Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer
出版年份 2016 全文链接
标题
Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF UROLOGY
Volume 23, Issue 5, Pages 360-369
出版商
Wiley
发表日期
2016-04-11
DOI
10.1111/iju.13091
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
- (2016) Marcello Tucci et al. EUROPEAN UROLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
- (2016) Claire L Vale et al. LANCET ONCOLOGY
- Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy
- (2016) Maxine Sun et al. JAMA Oncology
- Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer
- (2016) Dawn L. Hershman et al. JAMA Oncology
- Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy
- (2016) Masaki Shiota et al. Frontiers in Oncology
- Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra
- (2015) K. Fizazi et al. ANNALS OF ONCOLOGY
- Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer
- (2015) Matthew R. Cooperberg et al. BJU INTERNATIONAL
- Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review
- (2015) Frank Kunath et al. BJU INTERNATIONAL
- Adverse effects of androgen-deprivation therapy in prostate cancer and their management
- (2015) Handoo Rhee et al. BJU INTERNATIONAL
- Novel agents for castration-resistant prostate cancer: Early experience and beyond
- (2015) Naohiro Fujimoto INTERNATIONAL JOURNAL OF UROLOGY
- SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Evan Y. Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5
- (2015) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
- (2015) Ethan M. Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
- (2015) Matthew Raymond Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
- (2015) Fred Saad et al. LANCET ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer
- (2015) Fred Saad et al. UROLOGY
- Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer
- (2015) Vahakn B Shahinian et al. BMC Urology
- Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer
- (2015) Sindy Magnan et al. JAMA Oncology
- Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists
- (2014) Laurence Klotz et al. EUROPEAN UROLOGY
- Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)
- (2014) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
- (2014) Bertrand Tombal et al. LANCET ONCOLOGY
- Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
- (2014) Peter Hoskin et al. LANCET ONCOLOGY
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
- (2014) Oliver Sartor et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix
- (2014) E. David Crawford et al. UROLOGY
- Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration
- (2013) Masaki Shiota et al. CURRENT CANCER DRUG TARGETS
- Prime Time for Intermittent Androgen Suppression
- (2013) Martin Gleave EUROPEAN UROLOGY
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2013) Axel Heidenreich et al. EUROPEAN UROLOGY
- Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12 Years of Follow-up
- (2013) Urs E. Studer et al. EUROPEAN UROLOGY
- Androgen-deprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke: A Nationwide Danish Population-based Cohort Study
- (2013) Christina G. Jespersen et al. EUROPEAN UROLOGY
- Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
- (2013) Peter C. Albertsen et al. EUROPEAN UROLOGY
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- (2013) Gwenaelle Gravis et al. LANCET ONCOLOGY
- Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
- (2013) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interaction between docetaxel resistance and castration resistance in prostate cancer: Implications of twist1, YB-1, and androgen receptor
- (2013) Masaki Shiota et al. PROSTATE
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer
- (2012) Masaki Shiota et al. ENDOCRINE-RELATED CANCER
- A Phase 3, Double-blind, Randomised, Parallel-group, Placebo-controlled Study of Oral Weekly Alendronate for the Prevention of Androgen Deprivation Bone Loss in Nonmetastatic Prostate Cancer: The Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) Study
- (2012) Laurence H. Klotz et al. EUROPEAN UROLOGY
- Lower Testosterone Levels With Luteinizing Hormone-Releasing Hormone Agonist Therapy Than With Surgical Castration: New Insights Attained by Mass Spectrometry
- (2012) Tim M. van der Sluis et al. JOURNAL OF UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer
- (2011) Masaki Shiota et al. CURRENT CANCER DRUG TARGETS
- Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer
- (2011) Masaki Shiota et al. FREE RADICAL BIOLOGY AND MEDICINE
- Antioxidant Therapy Alleviates Oxidative Stress by Androgen Deprivation and Prevents Conversion From Androgen Dependent to Castration Resistant Prostate Cancer
- (2011) Masaki Shiota et al. JOURNAL OF UROLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- SOD Mimetics: A Novel Class of Androgen Receptor Inhibitors That Suppresses Castration-Resistant Growth of Prostate Cancer
- (2011) R. Thomas et al. MOLECULAR CANCER THERAPEUTICS
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Combined androgen blockade with bicalutamide for advanced prostate cancer
- (2009) Hideyuki Akaza et al. CANCER
- Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics
- (2009) Bertrand Tombal et al. EUROPEAN UROLOGY
- Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
- (2009) Matthew R. Smith et al. JOURNAL OF UROLOGY
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
- (2009) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression
- (2009) M Shiota et al. ONCOGENE
- Does Oral Antiandrogen Use Before Leuteinizing Hormone-releasing Hormone Therapy in Patients With Metastatic Prostate Cancer Prevent Clinical Consequences of a Testosterone Flare?
- (2009) William K. Oh et al. UROLOGY
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
- (2008) Laurence Klotz et al. BJU INTERNATIONAL
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now